Intracranial hemorrhage had not been seen in this sub-group. in 10 of just one 1,784 kids and in 6 of 340 adults. Co-morbidity was seen in 3.9% of children and in 30% of adults. Bone tissue marrow aspiration and lab exams (antinuclear antibodies, individual immunodeficiency and hepatitis C pathogen) had been performed more often in adults. Children and adults were followed with a watch and wait strategy in 20% and in 29%, respectively. Immunoglobulins were used more frequently in children and corticosteroids in adults. == Conclusions == Comparative data of Tafenoquine children and adults with newly diagnosed immune thrombocytopenia revealed similarities in presenting platelet counts and in bleeding, whereas differences occurred in co-morbidity, diagnostic procedures and therapy. Keywords:immune thrombocytopenia, newly diagnosed, similarities, differences, comparative data == Introduction == Immune thrombocytopenia (ITP), formerly known as idiopathic or immune thrombocytopenic purpura, is an acquired bleeding diathesis resulting from premature platelet destruction, reduced platelet production or a combination of both.1,2Primary ITP is defined as isolated thrombocytopenia in the absence of an Tafenoquine identified etiology or illness. Secondary ITP assumes the presence of a concurrent underlying disorder responsible for disturbed immune function leading to thrombocytopenia. The list of such disorders is extensive and may include autoimmune diseases (e.g. systemic lupus erythematosus or antiphospholipid syndrome), lymphoproliferative disorders, and chronic infections (e.g.Helicobacter pylori, human immunodeficiency virus or hepatitis C virus) in addition to many others.3ITP occurs across all age groups. The estimated incidence in children is approximately 1.9 to 6.4 cases per 100,000 per year and for adults 3.3 per 100,000 per year.4Retrospective data, consensus statements, expert opinion and textbooks suggest that childhood and adult onset ITP have distinctly different laboratory findings and clinical features.59 Due to the rarity of ITP, and the paucity of prospective clinical trial data, the Intercontinental Cooperative ITP Study Group (ICIS) was founded in 1997 by an international panel of hematologists with the goal of establishing a worldwide network of physicians and researchers to collect data to better define the natural history of childhood ITP, in addition to questions concerning diagnosis and therapy, including early predictors of chronic ITP (www.itpbasel.ch). In 2002, ICIS established the Pediatric and Adult Registry on Chronic ITP (PARC ITP). This international, multi-center registry was designed to collect prospective laboratory and clinical data from children and adults with newly diagnosed ITP and to follow them continuously over time. The information in the database will be used to compare the laboratory and clinical features of pediatric and adult ITP, to analyze the heterogeneity and natural history of the disorder across the different age groups, to validate its diagnosis and management, and to identify new patient selection criteria for future trials. This investigation is restricted to the query of the PARC ITP Registry assessing clinical findings at the time of initial diagnosis, with the aim of comparing the differences between children and adults with ITP. The findings suggest that the differences observed between the two age groups are smaller than expected. == Design and Methods == Tafenoquine == Registry design == The structure of the Registry is similar to its predecessors; ICIS Registry I10and ICIS Registry II.11Patient registration is based on voluntary participation by physicians involved in the management of patients with ITP worldwide. Mouse monoclonal to ALDH1A1 Information about the Registry was made available on the internet (www.itpbasel.ch), at scientific conferences and symposia, meetings organized by ICIS, and publication of regular newsletters and journal supplements. The ICIS questionnaires are case based, designed to collect prospective clinical and laboratory data at first presentation and throughout the course of ITP, and intended to generate hypotheses with the potential to add side-studies to the main database. The PARC-ITP Registry opened in May 2004 to obtain prospective data on the clinical presentations, natural history, and clinical course of children older than two months of age and Tafenoquine adults with newly diagnosed ITP. Data was submitted electronically directly to the ICIS coordinating.